Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novozymes Biopharma Announces Collaboration with Almac

Published: Tuesday, October 22, 2013
Last Updated: Tuesday, October 22, 2013
Bookmark and Share
Combined service offers drug development companies efficiencies in time and resource.

Novozymes Biopharma has announced its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

The collaboration will allow clients to utilize Almac’s world-class manufacturing assets and protein conjugation capability to link Novozymes’ Recombumin® Flex technology successfully to their peptide and small molecule drugs.

This subsequently improves the pharmacokinetics and has already been shown to improve drug targeting in oncology and rheumatoid arthritis. Collaborations with commercial partners have already begun and will continue to expand in early 2014.

Novozymes and Almac have a solid history of cooperation in peptide and small molecule conjugation projects. The formalization of this collaboration offers drug developers the immediate benefit of continuity of service provision through the stages of clinical development -delivering efficiencies in time and internal resource, whilst increasing the chances of clinical success.

Clients will also benefit from extensive experience in product and service provision to the pharmaceutical industry with access to a comprehensive level of both technical and regulatory support.

Novozymes’ Recombumin® Flex technology will be the focal point of this collaboration. Novozymes has modified the amino acid sequence of human albumin to increase its receptor affinity, providing novel properties including improved half-life extension and drug targeting.

This technology naturally complements Almac’s expertise in peptide and small molecule manufacturing, and can also be allied to its world-class protein conjugation technology offerings. As a result, clients will be able to successfully use Almac’s technology to link Recombumin® Flex to their drug products as part of one contract service offering.

“By working alongside Almac, we are confident that we will be able to create more opportunities for developers seeking to benefit from the Recombumin® Flex technology,” stated Dermot Pearson, Marketing Director at Novozymes Biopharma. “the advantage of working with two companies well versed in providing products and services to the pharmaceutical industry is that customers gain the assurance that their needs will be provided for, not just in the short term, but right through to commercial supply.”

Denis Geffroy, VP Business Development for Almac stated: “This alliance has clear benefits for companies involved in both drug development and delivery technologies: a complete service can be recommended utilizing the core expertise of both parties at an early stage of clinical development, thus significantly enhancing the success of drug development programmes.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group Expands Asia Pacific Presence
Company opens new regional headquarters and clinical trial supply facility in Singapore.
Thursday, July 16, 2015
Almac Expands US & UK Commercial Facilities
Investments of over $20m enhance Almac’s commercial facilities on both sides of the Atlantic.
Tuesday, October 22, 2013
Almac Announces Further Expansion and 229 New Jobs
Dual expansion with completion of a new non-GMP drug development facility.
Monday, June 17, 2013
Almac Launches US Commercial Packaging Operations in Audubon
Company also announces launch of new client partnership.
Monday, May 20, 2013
Almac Receives FDA Inspection Approval
Successful inspection of analytical facilities at Almac’s Craigavon Headquarters, Northern Ireland from the US FDA.
Thursday, February 21, 2013
Almac Doubles Drug Product Development Capacity with a New Non-GMP Facility
New facility offers clients greater flexibility and speed in formulation and process development.
Tuesday, January 15, 2013
Charlie Morris Appointed to Almac’s Clinical Technologies Executive Team
Mr. Morris joins Almac as Vice President of new products and services.
Thursday, December 13, 2012
Almac Concludes Commercial API Manufacturing Facility Expansion Plans
Almac’s expansion is near completion and will be operational by the end of the year.
Tuesday, October 09, 2012
Almac Expands UK Commercial Capacity
Acquisition of new Noack N 623 blister packaging line from Romaco.
Friday, October 05, 2012
Almac Installs Uhlmann Blister Line in New US Commercial Packaging Facility
Acquisition of a high-speed blister line in Audubon, PA.
Monday, July 02, 2012
Almac Introduces QP Facilitation Programme for Conducting Trials in the European Union
Programme vastly simplifies and expedites the QP release process.
Thursday, June 14, 2012
Almac Adds High-Speed Clinical Trial Blistering Equipment at US HQ
Almac acquires PharmaWorks TF3 machine to fulfil customer's needs by increasing blistering capacity.
Tuesday, May 15, 2012
Almac Strengthens Board with Appointment of New Financial Director
Kevin Stephens’ promotion to FD is set to further enhance the Group’s financial performance and programme for international growth.
Tuesday, April 10, 2012
New Building will Help Almac Serve Customers from Argentina to Zimbabwe
New £3m building opens at Craigavon, UK headquarters.
Tuesday, April 10, 2012
Almac Expands in US with Addition of Commercial Packaging Facility in Audubon, PA.
Expansion with $10m investment in a new 100,000ft2 commercial facility in Audubon.
Monday, March 12, 2012
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!